Exelixis, Inc. (EXEL): Operating Income
$872.19M
Year ended 2026-01-02, Fiscal 2025
$971.51M
Trailing 12 months to 2026-07-03
+63.0%
3-year compound annual growth
+51.3%
5-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $872.19M | +44.3% | 2026-02-10, From 2025-01-04 |
| 2025-01-03, Fiscal 2024 | $604.62M | +253.8% | 2026-02-10, From 2023-12-30 |
| 2023-12-29 | $170.88M | -15.2% | 2026-02-10, From 2022-12-31 |
| 2022-12-30 | $201.48M | -29.7% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $286.67M | +160.5% | 2024-02-06, From 2021-01-02 |
| 2021-01-01, Fiscal 2020 | $110.06M | -70.2% | 2023-02-07, From 2020-01-04 |
| 2020-01-03, Fiscal 2019 | $369.47M | -15.8% | 2022-02-18, From 2018-12-29 |
| 2018-12-28 | $438.86M | +164.5% | 2021-02-11, From 2018-01-01 |
| 2017-12-29 | $165.91M | n/m | 2020-02-25, From 2016-12-31 |
| 2016-12-30 | -$28.12M | n/m | 2019-02-22, From 2016-01-02 |
| 2016-01-01, Fiscal 2015 | -$121.42M | n/m | 2018-02-26, From 2015-01-03 |
| 2014-12-31 | -$224.46M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$200.73M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$122.44M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $89.53M | n/m | 2014-02-20, From 2011-01-01 |
| 2010-12-31 | -$91.40M | n/m | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | -$121.91M | n/a | 2012-02-22, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $872.19M | +44.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $465.85M | +376.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$3.07B | n/m |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $619.10M | +8.5% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $469.01M | -15.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Novavax Inc (NVAX) | 2025-12-31 | $452.80M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗